4/A: Axim Biotechnologies CEO Acquires Convertible Notes
SEC Form 4/A
John W. Huemoeller II, CEO of Axim Biotechnologies, acquired convertible notes that can be converted into shares of the company's common stock.
Summary
- John W. Huemoeller II, the CEO of Axim Biotechnologies, filed an amendment to a previous Form 4.
- The report details the acquisition of two convertible notes.
- One note has a face value of $250,000 and is convertible into common stock at $0.01 per share, exercisable from January 23, 2026, and expiring on January 24, 2033.
- The other note has a face value of $250,000 and is convertible into common stock at $0.02 per share, exercisable from March 15, 2024, and expiring on March 1, 2034.
- Following these transactions, Huemoeller beneficially owns 30,000,000 shares underlying the $0.01 convertible note and 42,500,000 shares underlying the $0.02 convertible note.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing the CEO's acquisition of convertible notes. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The acquisition of convertible notes by the CEO could be seen as a sign of confidence in the company's future prospects, but it also increases the potential for dilution of existing shareholders if the notes are converted to equity.
Stakeholder Impact
- Shareholders may experience dilution if the convertible notes are converted into common stock.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of earliest transaction and acquisition of convertible notes. |
| 03/19/2024 | Date of original filing and signature date. |
| 01/23/2026 | Date the $0.01 convertible note becomes exercisable. |
| 01/24/2033 | Expiration date of the $0.01 convertible note. |
| 03/01/2034 | Expiration date of the $0.02 convertible note. |
Keywords
Convertible Notes, Form 4, Beneficial Ownership, AXIM Biotechnologies, Huemoeller, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.